。ファミリーマートや
Since July, when stock market volatility began to increase, the pharmaceutical sector, which is considered defensive, has shown strength.The pharmaceutical sector is strongly included.。TOPIX（東証株価指数）は7月11日に高値を付けて以降、米景気懸念からの売りや8月初頭の暴落を経て現在（30日）までに7％下落した。一方、TOPIXをセクター別にした医薬品指数は4％上昇し、さらに上値を追っている。7月まで好調だった半導体関連銘柄を多く含む機械指数（14％下落）、銀行業指数（13％下落）に比べても大きくアウトパフォームスイス製薬大手ロシュ傘下の医薬品大手。抗体・バイオで先行している。抗がん剤に強み。血友病薬「ヘムライブラ」が欧州を軸に成長。中外製薬は医薬品株に対する投資人気は少なくとも半年程度は続きそうだと予想に経口の肥満症薬候補「オルフォルグリプロン」の権利を譲渡
(Rate of increase from July 11th to August 30th)
Obesity drug-related $Chugai Pharmaceutical (4519.JP)$ (16%) and high-performing $Otsuka Holdings (4578.JP)$(19%) continues to rise amid a long-term upward trend. It has downwardly revised its performance forecast four times for the fiscal year ending in March 2024. $Astellas Pharma (4503.JP)$(9%) is continuing to operate at a loss. $Sumitomo Pharma (4506.JP)$There has been renewed buying interest in stocks that have been performing poorly, such as (64%) which is engaged in regenerative medicine and has attracted a lot of attention. $CellSource (4880.JP)$(10%) also experienced a significant increase.
(In market capitalization order)
◆ $Chugai Pharmaceutical (4519.JP)$
A leading pharmaceutical company under the Swiss healthcare giant Roche. It is at the forefront of antibody and biotechnology. It has a strong presence in cancer drugs. Its hemophilia drug, Hemlibra, is experiencing growth primarily in Europe. Chugai Pharmaceutical isThe USA announced on the 13th that founder Howard Schultz will retire on the same day. On that day, the company appointed Wei Chang, former advisor to China's largest e-commerce company Alibaba Group, to its board of directors. $Eli Lilly and Co (LLY.US)$The rights to the oral obesity drug candidate "Orforogrippron" have been transferred, and if it is sold, royalty income will be obtained. Eli Lilly's obesity drug "Zepbound" is already on sale as an injection, but Orforgliphron is expected to be commercialized as an oral medication, and there are expectations that the demand will increase. Sales revenue (sales) for the fiscal year ending in December 2024 is 17 trillion 7 billion yen, a decrease of 3.7% compared to the previous year, and core current profit is 335.5 billion yen, an increase of 0.6% . Domestic demand has decreased due to factors such as drug price revisions. There is no change in the outlook for operating profit and current profit, which are the highest in history. The closing price on the 30th is 13% higher than the average analyst target stock price.」と8月中旬のリポートでコメント。The obesity drug 'Zepbound' is an injectable drug.However, Orfolgripiron isan oral medicationand there are expectations that it may be put into practical use as a pill, with hopes of increasing demand. For the sales revenue for the fiscal year ending December 2024, there is a 3.7% decrease from the previous period to 1.7 trillion yen, while core net profit increased by 0.6% to 335.5 billion yen. The domestic market declined due to factors such as retroactive payment revision. There is no change in the performance outlook that operating profit and net income will reach record highs.
◆ $Chugai Pharmaceutical (4519.JP)$
A leading pharmaceutical company under the Swiss healthcare giant Roche. It is at the forefront of antibody and biotechnology. It has a strong presence in cancer drugs. Its hemophilia drug, Hemlibra, is experiencing growth primarily in Europe. Chugai Pharmaceutical isThe USA announced on the 13th that founder Howard Schultz will retire on the same day. On that day, the company appointed Wei Chang, former advisor to China's largest e-commerce company Alibaba Group, to its board of directors. $Eli Lilly and Co (LLY.US)$The rights to the oral obesity drug candidate "Orforogrippron" have been transferred, and if it is sold, royalty income will be obtained. Eli Lilly's obesity drug "Zepbound" is already on sale as an injection, but Orforgliphron is expected to be commercialized as an oral medication, and there are expectations that the demand will increase. Sales revenue (sales) for the fiscal year ending in December 2024 is 17 trillion 7 billion yen, a decrease of 3.7% compared to the previous year, and core current profit is 335.5 billion yen, an increase of 0.6% . Domestic demand has decreased due to factors such as drug price revisions. There is no change in the outlook for operating profit and current profit, which are the highest in history. The closing price on the 30th is 13% higher than the average analyst target stock price.」と8月中旬のリポートでコメント。The obesity drug 'Zepbound' is an injectable drug.However, Orfolgripiron isan oral medicationand there are expectations that it may be put into practical use as a pill, with hopes of increasing demand. For the sales revenue for the fiscal year ending December 2024, there is a 3.7% decrease from the previous period to 1.7 trillion yen, while core net profit increased by 0.6% to 335.5 billion yen. The domestic market declined due to factors such as retroactive payment revision. There is no change in the performance outlook that operating profit and net income will reach record highs.
◆ $Otsuka Holdings (4578.JP)$
The rights to the oral obesity drug candidate "Orforogrippron" have been transferred, and if it is sold, royalty income will be obtained. Eli Lilly's obesity drug "Zepbound" is already on sale as an injection, but Orforgliphron is expected to be commercialized as an oral medication, and there are expectations that the demand will increase. Sales revenue (sales) for the fiscal year ending in December 2024 is 17 trillion 7 billion yen, a decrease of 3.7% compared to the previous year, and core current profit is 335.5 billion yen, an increase of 0.6% . Domestic demand has decreased due to factors such as drug price revisions. There is no change in the outlook for operating profit and current profit, which are the highest in history. The closing price on the 30th is 13% higher than the average analyst target stock price.Antipsychotic drugs and anticancer drugs are the mainstay. Functional foods such as "Pocari Sweat" are also expanding. A loss of about 100 billion yen due to impairment losses was recorded in the first half of the year due to the discontinuation of the development of Alzheimer's disease-related drugs. On August 1, it announced a share buyback of up to 50 billion yen. Consolidated sales revenue (sales) for the fiscal year ending December 2024 is 2 trillion 315 billion yen, an increase of 14.7% from the previous period, and net profit is expected to be 240 billion yen, an increase of 97.3%.Antipsychotic drugs and anticancer drugs are the mainstay. Functional foods such as "Pocari Sweat" are also expanding. A loss of about 100 billion yen due to impairment losses was recorded in the first half of the year due to the discontinuation of the development of Alzheimer's disease-related drugs. On August 1, it announced a share buyback of up to 50 billion yen. Consolidated sales revenue (sales) for the fiscal year ending December 2024 is 2 trillion 315 billion yen, an increase of 14.7% from the previous period, and net profit is expected to be 240 billion yen, an increase of 97.3%.Antipsychotic drugs and anticancer drugs are the mainstay. Functional foods such as "Pocari Sweat" are also expanding. A loss of about 100 billion yen due to impairment losses was recorded in the first half of the year due to the discontinuation of the development of Alzheimer's disease-related drugs. On August 1, it announced a share buyback of up to 50 billion yen. Consolidated sales revenue (sales) for the fiscal year ending December 2024 is 2 trillion 315 billion yen, an increase of 14.7% from the previous period, and net profit is expected to be 240 billion yen, an increase of 97.3%.Antipsychotic drugs and anticancer drugs are the mainstay. Functional foods such as "Pocari Sweat" are also expanding. A loss of about 100 billion yen due to impairment losses was recorded in the first half of the year due to the discontinuation of the development of Alzheimer's disease-related drugs. On August 1, it announced a share buyback of up to 50 billion yen. Consolidated sales revenue (sales) for the fiscal year ending December 2024 is 2 trillion 315 billion yen, an increase of 14.7% from the previous period, and net profit is expected to be 240 billion yen, an increase of 97.3%.抗精神病薬「レキサルティ」、抗がん剤「ロンサーフ」が好調。
The rights to the oral obesity drug candidate "Orforogrippron" have been transferred, and if it is sold, royalty income will be obtained. Eli Lilly's obesity drug "Zepbound" is already on sale as an injection, but Orforgliphron is expected to be commercialized as an oral medication, and there are expectations that the demand will increase. Sales revenue (sales) for the fiscal year ending in December 2024 is 17 trillion 7 billion yen, a decrease of 3.7% compared to the previous year, and core current profit is 335.5 billion yen, an increase of 0.6% . Domestic demand has decreased due to factors such as drug price revisions. There is no change in the outlook for operating profit and current profit, which are the highest in history. The closing price on the 30th is 13% higher than the average analyst target stock price.Antipsychotic drugs and anticancer drugs are the mainstay. Functional foods such as "Pocari Sweat" are also expanding. A loss of about 100 billion yen due to impairment losses was recorded in the first half of the year due to the discontinuation of the development of Alzheimer's disease-related drugs. On August 1, it announced a share buyback of up to 50 billion yen. Consolidated sales revenue (sales) for the fiscal year ending December 2024 is 2 trillion 315 billion yen, an increase of 14.7% from the previous period, and net profit is expected to be 240 billion yen, an increase of 97.3%.Antipsychotic drugs and anticancer drugs are the mainstay. Functional foods such as "Pocari Sweat" are also expanding. A loss of about 100 billion yen due to impairment losses was recorded in the first half of the year due to the discontinuation of the development of Alzheimer's disease-related drugs. On August 1, it announced a share buyback of up to 50 billion yen. Consolidated sales revenue (sales) for the fiscal year ending December 2024 is 2 trillion 315 billion yen, an increase of 14.7% from the previous period, and net profit is expected to be 240 billion yen, an increase of 97.3%.Antipsychotic drugs and anticancer drugs are the mainstay. Functional foods such as "Pocari Sweat" are also expanding. A loss of about 100 billion yen due to impairment losses was recorded in the first half of the year due to the discontinuation of the development of Alzheimer's disease-related drugs. On August 1, it announced a share buyback of up to 50 billion yen. Consolidated sales revenue (sales) for the fiscal year ending December 2024 is 2 trillion 315 billion yen, an increase of 14.7% from the previous period, and net profit is expected to be 240 billion yen, an increase of 97.3%.Antipsychotic drugs and anticancer drugs are the mainstay. Functional foods such as "Pocari Sweat" are also expanding. A loss of about 100 billion yen due to impairment losses was recorded in the first half of the year due to the discontinuation of the development of Alzheimer's disease-related drugs. On August 1, it announced a share buyback of up to 50 billion yen. Consolidated sales revenue (sales) for the fiscal year ending December 2024 is 2 trillion 315 billion yen, an increase of 14.7% from the previous period, and net profit is expected to be 240 billion yen, an increase of 97.3%.抗精神病薬「レキサルティ」、抗がん剤「ロンサーフ」が好調。
◆ $Astellas Pharma (4503.JP)$
医薬品国内2位。主力の前立腺がん薬「イクスタンジ」の販売が好調。尿路上皮がん向け治療薬の販売も伸びている。イクスタンジは27年米国を皮切りに特許が切れることから後発薬への切り替えによる販売減が懸念されている。8月1日発表した25年3月期通期見通しは、連結売上収益は前期比2.9％増の１兆650 billion円、純利益は76％増の30 billion円。コアベースでは、売上収益は2.9％増、コア当期利益は16.7％減の186 billion円となる。外資アナリストは決算発表を受け、「２Qの上方修正が期待できる内容」とリポートでコメントした。また、同社は8月20日、米ファイザーと共同で開発を進める抗がん剤「エンホルツマブ・ベドチン」について、中国の国家薬品監督管理局の医薬品評価センターから尿路上皮がん患者向けの治療薬として承認を取得Announced it as mentioned.
医薬品国内2位。主力の前立腺がん薬「イクスタンジ」の販売が好調。尿路上皮がん向け治療薬の販売も伸びている。イクスタンジは27年米国を皮切りに特許が切れることから後発薬への切り替えによる販売減が懸念されている。8月1日発表した25年3月期通期見通しは、連結売上収益は前期比2.9％増の１兆650 billion円、純利益は76％増の30 billion円。コアベースでは、売上収益は2.9％増、コア当期利益は16.7％減の186 billion円となる。外資アナリストは決算発表を受け、「２Qの上方修正が期待できる内容」とリポートでコメントした。また、同社は8月20日、米ファイザーと共同で開発を進める抗がん剤「エンホルツマブ・ベドチン」について、中国の国家薬品監督管理局の医薬品評価センターから尿路上皮がん患者向けの治療薬として承認を取得Announced it as mentioned.
◆ $Sumitomo Pharma (4506.JP)$
$Sumitomo Chemical (4005.JP)$It is a quasi-major pharmaceutical company under the umbrella. From the term ending in March 2023,It has fallen into the red and has been promoting structural reforms.There is a growing expectation that it will turn into a profit in the next term, ending in March 2026.The core products are overactive bladder treatment drug 'Gemtesa,' prostate cancer treatment drug 'Orgovyx,' and uterine fibroid treatment drug 'Myfembree.' The financial performance for the 1st quarter of the term ending in March 2025, announced on July 31st, has improved significantly,There is a favorable response to the announcement of the recruitment of about 700 early retirees as part of the structural reform of the domestic business, and buying has gained momentum. Especiallythe structural reform of the domestic business and the announcement of the recruitment of about 700 early retirees have been positively received and buying has gained momentum. Especiallyespecially theExpecting a sales beat of Orgovyx in the USABeing sold. Citi changed its rating from 'sell' to 'hold' on August 7th, JP Morgan on the 15th, and SMBC Nikko on the 21st raised its rating. The stock price surged but has since been held back by the high from July 2023.
$Sumitomo Chemical (4005.JP)$It is a quasi-major pharmaceutical company under the umbrella. From the term ending in March 2023,It has fallen into the red and has been promoting structural reforms.There is a growing expectation that it will turn into a profit in the next term, ending in March 2026.The core products are overactive bladder treatment drug 'Gemtesa,' prostate cancer treatment drug 'Orgovyx,' and uterine fibroid treatment drug 'Myfembree.' The financial performance for the 1st quarter of the term ending in March 2025, announced on July 31st, has improved significantly,There is a favorable response to the announcement of the recruitment of about 700 early retirees as part of the structural reform of the domestic business, and buying has gained momentum. Especiallythe structural reform of the domestic business and the announcement of the recruitment of about 700 early retirees have been positively received and buying has gained momentum. Especiallyespecially theExpecting a sales beat of Orgovyx in the USABeing sold. Citi changed its rating from 'sell' to 'hold' on August 7th, JP Morgan on the 15th, and SMBC Nikko on the 21st raised its rating. The stock price surged but has since been held back by the high from July 2023.
◆ $CellSource (4880.JP)$
The main business involves receiving cells or blood from medical institutions, processing them in a way that can be used for regenerative medicine. It also involves infertility treatment.The president is Mr. Takashi Sawada, a former president of FamilyMart.FamilyMart and $Unicharm (8113.JP)$are collaborating with Cellsource to introduce a welfare system that allows cheaper use of egg freezing and storage services than usual. They expect sales for the fiscal year ending October 2024 to increase by 19% to 5.3 billion yen, while net profit is expected to decrease by 22% to 0.7 billion yen. On July 16th, they announced that they had been entrusted to operate an online explanatory session for those targeted for egg freezing in Tokyo. Nomura Securities' investment decision is "buy" with a target stock price of 1600 yen.
The main business involves receiving cells or blood from medical institutions, processing them in a way that can be used for regenerative medicine. It also involves infertility treatment.The president is Mr. Takashi Sawada, a former president of FamilyMart.FamilyMart and $Unicharm (8113.JP)$are collaborating with Cellsource to introduce a welfare system that allows cheaper use of egg freezing and storage services than usual. They expect sales for the fiscal year ending October 2024 to increase by 19% to 5.3 billion yen, while net profit is expected to decrease by 22% to 0.7 billion yen. On July 16th, they announced that they had been entrusted to operate an online explanatory session for those targeted for egg freezing in Tokyo. Nomura Securities' investment decision is "buy" with a target stock price of 1600 yen.
◆ $Shionogi (4507.JP)$: After the market close on August 30, announced stock splits and increased dividends.
◆ $Daiichi Sankyo (4568.JP)$Foreign analysts commented in a mid-August report, "Anticipating an upward revision of the full-year company plan in the 2nd quarter earnings report."
◆ $PeptiDream (4587.JP)$Expanding partnership with Swiss Novartis. The partnership's one-time payment will contribute to performance.
◆ $Nxera Pharma (4565.JP)$(Former Sosei Group): Attention to the trial results of drugs for schizophrenia and other conditions
◆ $SanBio (4592.JP)$: Aim to start shipping the traumatic brain injury treatment drug "Akugo" next year
-moomoo News Kathy
Source: IR materials from each company, Bloomberg, Yonkiho, moomoo
Source: IR materials from each company, Bloomberg, Yonkiho, moomoo
Disclaimer: Moomoo Technologies Inc. is providing this content for information and educational use only.
Read more
Comment
Sign in to post a comment
人類 : Mostly Zoro, but Defenseive?!